Home/Filings/4/0001140361-19-007331
4//SEC Filing

RTW INVESTMENTS, LP 4

Accession 0001140361-19-007331

CIK 0001281895other

Filed

Apr 17, 8:00 PM ET

Accepted

Apr 18, 4:14 PM ET

Size

9.9 KB

Accession

0001140361-19-007331

Insider Transaction Report

Form 4
Period: 2019-04-16
WONG RODERICK
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2019-04-16$17.50/sh+550,005$9,625,08817,057,324 total(indirect: By RTW)
RTW INVESTMENTS, LP
Director10% OwnerOther
Transactions
  • Purchase

    Common Stock

    2019-04-16$17.50/sh+550,005$9,625,08817,057,324 total(indirect: By RTW)
Transactions
  • Purchase

    Common Stock

    2019-04-16$17.50/sh+550,005$9,625,08817,057,324 total(indirect: By RTW)
Footnotes (3)
  • [F1]Represents shares of common stock purchased from the underwriters pursuant to an underwritten public offering by the Issuer (the "Offering"). The Offering closed on April 18, 2019 and the shares were purchased at the public offering price of $17.50 per share.
  • [F2]The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Special Purpose Fund I, LLC (collectively, the "Funds"), which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW.
  • [F3]Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of his pecuniary interest therein. The shares reported above exclude 113,641 shares of common stock indirectly beneficially held by Dr. Yalamanchi through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016.

Issuer

ROCKET PHARMACEUTICALS, INC.

CIK 0001281895

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001493215

Filing Metadata

Form type
4
Filed
Apr 17, 8:00 PM ET
Accepted
Apr 18, 4:14 PM ET
Size
9.9 KB